News | Patient Monitors | August 16, 2018

Lexington Biosciences Concludes Initial HeartSentry Clinical Study

Company prepares for multicenter pivotal clinical study

Lexington Biosciences Concludes Initial HeartSentry Clinical Study

August 16, 2018 — Lexington Biosciences Inc. recently announced the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research.

As part of the clinical study protocol, the data acquired from this initial study of the HeartSentry device effectively provides critical guidance for key aspects of the pivotal study itself. With the conclusion of the initial term of work at Diablo Clinical Research, the company moves ahead under the continued leadership of Geoff Tison, M.D. M.P.H, into an advanced stage multicenter trial.

Lexington Biosciences will immediately embark on the implementation of agreements with several trial locations which have been previously contacted as potential study sites. Tison will utilize the initial data to update patient examination protocols as required. Both he and the company will work with each facility to begin enrollment of a significantly larger patient sample from their respective clinical databases.

HeartSentry was designed as a diagnostic device offering a new approach to non-invasive measurement and monitoring of cardiovascular health by assessing the function of a patient’s vascular endothelium, the innermost lining of the cardiovascular system. Lexington Biosciences designed HeartSentry to be accurate, quick and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.

For more information: www.lexingtonbiosciences.com

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init